{"id":385537,"date":"2020-11-19T16:05:20","date_gmt":"2020-11-19T21:05:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385537"},"modified":"2020-11-19T16:05:20","modified_gmt":"2020-11-19T21:05:20","slug":"pra-health-sciences-appoints-senior-fda-official-to-lead-new-global-center-of-excellence-for-decentralized-clinical-trial-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pra-health-sciences-appoints-senior-fda-official-to-lead-new-global-center-of-excellence-for-decentralized-clinical-trial-strategy\/","title":{"rendered":"PRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial Strategy"},"content":{"rendered":"

\nDr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA\u2019s industry-leading DCT practice
\n<\/h2>\n
\n

RALEIGH, N.C. , Nov. 19, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the appointment of Isaac Rodriguez-Chavez, PhD, MHS, MS, as Senior Vice President, Scientific and Clinical Affairs. He will lead the company\u2019s Global Center of Excellence for Decentralized Clinical Trial (DCT) Strategy. Dr. Rodriguez-Chavez\u2019s responsibilities will involve the continued growth and development of PRA\u2019s industry-leading decentralized clinical trial strategy, regulatory framework creation, and clinical trial modernization.<\/p>\n

Dr. Rodriguez-Chavez has more than 32 years of experience in virology, microbiology, immunology, vaccinology and viral oncology, including basic, pre-clinical and clinical research (phase I-IV). Most recently as a Senior Officer for Clinical Research Methodologies, Regulatory Compliance, and Medical Policy Development with the U.S. Food and Drug Administration\u2019s Center for Drug Evaluation and Research (CDER), he led the development of guidance around decentralized clinical trials using digital health technologies. With the FDA, he evaluated and modernized clinical research protocols that impact multiple disease areas.<\/p>\n

\u201cWe are honored to have one of the pioneers in decentralized clinical trials and an established expert in clinical trial modernization join PRA Health Sciences,\u201d said Colin Shannon, President and Chief Executive Officer at PRA. “The clinical drug development paradigm continues to evolve into a more decentralized model to better align with how healthcare is delivered to individuals. By pairing Dr. Rodriguez-Chavez, one of the leading experts in decentralized clinical trials, with PRA\u2019s state-of-the-art DCT platform, we will modernize the clinical trial process.\u201d<\/p>\n

\u201cI am honored to join PRA Health Sciences to lead the Global Center of Excellence for Decentralized Clinical Trial Strategy and enable their implementation with novel digital health technologies,\u201d said Dr. Rodriguez-Chavez. \u201cPRA Health Sciences has the vanguard infrastructure, human capital, and experience to provide excellence in a global suite of clinical research and healthcare services. We are currently experiencing an exponential adoption of modern clinical trial designs in the field, including decentralized clinical trials, and I am truly honored to help lead the change. Importantly, PRA Health Sciences also has the pulse and voice of trial participants and the right approach to assist individuals with their health using the latest innovations in health care systems.\u201d<\/p>\n

Prior to his work with the FDA, Dr. Rodriguez-Chavez was founder and CEO of 4Biosolutions Consulting and was the Vice President for Research at the Texas Biomedical Research Institute. Before that, he was the Director of the AIDS & Immunosuppression Program at the National Institute of Dental and Craniofacial Research, National Institutes of Health (NIH). Dr. Rodriguez-Chavez also held the position of Senior Clinical Scientist at Schering Plough Corporation and the Director of a portfolio for HIV Vaccines at the National Institutes of Allergy and Infectious Diseases, NIH.<\/p>\n

Dr. Rodriguez-Chavez also serves the clinical research community in many capacities, including:<\/p>\n